Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proton Therapy with Capecitabine for Rectal Cancer
NCT00503932Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2007
- Primary completion
- Apr 2008
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
A Phase 2 trial of capecitabine in rectal cancer, sponsored by University of Texas MD Anderson Cancer Center. Planned start Jul 2007; status: withdrawn.
02
Drugs
capecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00503932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00503932.